Treatment
Temozolomide clinical trials
We’re tracking 147 recruiting studies that include Temozolomide, each written for real people, not researchers, below.
Recruiting studies
- NCT06827717RecruitingPhase 2
Liposomal irinotecan combo for advanced Ewing sarcoma
This trial tests a combination of three drugs (liposomal irinotecan, temozolomide, and fluzoparib) for people with Ewing sarcoma that has spread or come back after first treatment. The goal is to see if this combination can help shrink tumors or slow the disease.
Guangzhou, GuangdongAges 18–75 - NCT07243470RecruitingPhase 1/Phase 2
Tarlatamab and temozolomide for brain tumors
This trial tests a new combination of two drugs (tarlatamab and temozolomide) for people with certain types of aggressive brain or central nervous system tumors that have come back or not responded to standard treatment. The hope is that this combination may work better against tumors that have a specific marker called DLL3.
AngersAges 12 years+ - NCT07025226RecruitingEarly Phase 1
Combination drugs and vaccine for glioma with remaining tumor
This trial tests a combination of several drugs and a vaccine to see if they can help treat glioma that has not gone away with previous treatment. It is for people whose tumors have certain gene changes and who still have some tumor remaining after standard therapy.
Rochester, MinnesotaAges 18 years+ - NCT07318831RecruitingPhase 2
Combination drug therapy for relapsed neuroblastoma
This trial tests a combination of four drugs (chidamide, dinutuximab beta, irinotecan, and temozolomide) for children whose neuroblastoma has returned or isn't responding to standard treatment. It aims to see if this mix can shrink the tumor or stop it from growing.
Tianjin, Tianjin MunicipalityAges Any age - NCT07375563RecruitingPhase 3
Chemoimmunotherapy with NK cells for high-risk neuroblastoma
This trial tests a combination of chemotherapy, immunotherapy, and natural killer (NK) cell therapy for children with high-risk neuroblastoma or ganglioneuroblastoma that has not responded to initial treatment or has come back after treatment. The goal is to see if this approach can help destroy cancer cells more effectively.
MoscowAges 1.5 years–18 years - NCT01649830RecruitingPhase 3
Temozolomide after radiation for low-grade brain tumor
This trial tests whether adding temozolomide chemotherapy after radiation helps control a type of low-grade brain tumor that was not fully removed. It may help reduce the chance the tumor comes back, compared with standard post-radiation care.
Guangzhou, GuangdongAges 18–60 - NCT07675070Recruiting
Temozolomide (Amitzo) for grade III or IV brain tumors
This trial studies a new form of the chemotherapy drug temozolomide (called Amitzo) in people with aggressive brain tumors (grade III or IV gliomas). It aims to see if the drug is safe and effective, and is for patients who need treatment for a new diagnosis or for tumors that have come back after standard care.
TehranAges 18–80 - NCT07569042RecruitingPhase 1/Phase 2
Continuing NBM-BMX and Temozolomide for Glioblastoma
This is a continuation study for patients who completed or are in the parent trial testing NBM-BMX (an experimental drug) combined with temozolomide (a standard brain-tumor chemotherapy) for newly diagnosed glioblastoma. If you tolerated the earlier treatment well and your doctor believes you could benefit, you may continue the same drugs in this rollover study.
Kaohsiung CityAges 18 years+ - NCT07599371RecruitingPhase 1/Phase 2
Ivoximab and temozolomide for recurring brain tumors
This trial tests a combination of two drugs—ivoximab (a new immunotherapy) and temozolomide (chemotherapy)—to treat gliomas (brain tumors) that have come back or stopped responding to prior treatment. The goal is to see if this combination is safe and effective.
Zhengzhou, HenanAges 18–85 - NCT05417594RecruitingPhase 1/Phase 2
Targeted drug study for advanced cancers with genetic changes
This Phase 1/2 study tests AZD9574 alone or with other cancer treatments in people with advanced solid tumors. It focuses on cancers with specific DNA repair gene changes (like BRCA1/2) or other matching tumor features, and aims to see if the treatment can shrink tumors and improve outcomes.
La Jolla, CaliforniaAges 18–130 - NCT05902169RecruitingPhase 3
Ultrasound with carboplatin for recurrent glioblastoma
This trial tests a device that opens the blood-brain barrier using ultrasound, allowing chemotherapy to reach the brain tumor better. It compares this approach to standard chemotherapy for people whose glioblastoma has returned.
Phoenix, ArizonaAges 18 years+ - NCT07195591RecruitingPhase 3
Starting radiation during brain cancer surgery vs. standard treatment
This trial tests putting radiation directly into the brain right after surgery for glioblastoma, instead of waiting for standard radiation later. It aims to see if this approach works better and is safe for you.
Scottsdale, ArizonaAges 18 years+ - NCT06172296RecruitingPhase 3
Dinutuximab plus transplant for high-risk neuroblastoma
This trial tests adding a targeted drug called dinutuximab to standard chemotherapy, surgery, and a stem cell transplant for children and young adults with a new diagnosis of high-risk neuroblastoma. The goal is to see if this combination helps more patients stay in remission.
Birmingham, AlabamaAges Up to 30 years - NCT05999994RecruitingPhase 2
Testing new drugs for children and young adults with cancer
This trial tests several experimental drugs for children and young adults with cancer. It aims to find safe and effective treatments by matching participants to one of several drug studies based on their cancer type and health.
Birmingham, AlabamaAges 1–39 - NCT07085338RecruitingPhase 2
N-803 with chemoimmunotherapy for relapsed neuroblastoma
This trial tests adding a new drug called N-803 to a standard chemo-immunotherapy combination for children and young adults with high-risk neuroblastoma that has come back or not responded to previous treatments. The goal is to see if this combination works better at fighting the cancer.
San Francisco, CaliforniaAges Up to 30 years - NCT06006273RecruitingPhase 1
Testing a new drug combo for children with returning solid tumors
This trial tests a new combination of three chemotherapy drugs (eribulin, irinotecan, and temozolomide) for children and young adults whose solid tumors have come back or not responded to standard treatment. The goal is to see if this combination is safe and effective.
Houston, TexasAges 1–25 - NCT04221035RecruitingPhase 3
Trial for children with high-risk neuroblastoma testing next steps
This Phase 3 study tests treatment strategies for children with high-risk neuroblastoma, aiming to improve how well the cancer responds and how long patients can stay in control. It compares different intensities and add-ons at key treatment steps depending on your child’s response and health.
Sydney, RandwickAges Up to 21 years - NCT04566380RecruitingPhase 2
Study for people already taking ONO-4538
This trial is for people who are already being treated with ONO-4538 (either alone or with other treatments) and can continue into an “extension/rollover” study. It checks how well ONO-4538 continues to work and is used safely over more time.
Kashiwa, ChibaAges 16 years+ - NCT07191431Recruiting
Study of drug combo for returning brain lymphoma
This trial tests a combination of drugs (Orelabrutinib and Selinexor) with either Methotrexate, Thiotepa, or Temozolomide for people whose brain lymphoma has come back or not responded to prior treatment. The goal is to see if this combination is safe and effective.
Shanghai, Shanghai MunicipalityAges 14–80 - NCT07104032RecruitingPhase 3
Tirabrutinib vs standard therapy for relapsed PCNSL
This study tests a new oral targeted drug called tirabrutinib against a standard treatment combination (rituximab plus temozolomide) for people whose primary central nervous system lymphoma has come back or not responded to prior therapy.
Phoenix, ArizonaAges 18 years+ - NCT07549321RecruitingPhase 2/Phase 3
Hu14 Immunotherapy for High-Risk Neuroblastoma in Children
This study tests a new antibody-based immunotherapy called hu14 for children and young adults with high-risk neuroblastoma (an aggressive childhood cancer that has spread). The treatment is designed to help the immune system fight cancer cells.
Aurora, ColoradoAges 1.5 years–18 years - NCT07310784RecruitingPhase 2
Testing LM103 for advanced melanoma
This trial tests a new drug called LM103 for people with advanced melanoma who have already tried several standard treatments, including immunotherapy. The goal is to see if LM103 can help shrink tumors when other treatments have stopped working.
Beijing, Beijing MunicipalityAges 18–75 - NCT06760117RecruitingPhase 1
Gene-guided chemo for kids with relapsed solid tumors
This trial tests a new combination of chemotherapy drugs (irinotecan, temozolomide, and vincristine) for children whose solid tumors have come back or not responded to standard treatment. It aims to see if a specific gene test can help doctors choose the right dose of irinotecan to reduce side effects.
Guangzhou, GuangdongAges Up to 18 years - NCT06739395RecruitingPhase 2
Precision cancer trial for patients out of standard options
This trial uses genetic testing of your tumor to match you with a targeted therapy. It is for people with advanced solid tumors who have exhausted or cannot tolerate standard treatments.
Tianjin, Tianjin MunicipalityAges 18 years+
Common questions
- Are there clinical trials studying Temozolomide?
- Yes. Clin2 currently lists 147 recruiting studies that include Temozolomide, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Temozolomide trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Temozolomide an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Temozolomide or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.